$4.67
9.85%
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US01438T1060
Symbol
ALDX

Aldeyra Therapeutics, Inc. Stock price

$4.67
-0.20 4.11% 1M
+0.67 16.75% 6M
-0.51 9.85% YTD
-0.55 10.54% 1Y
-2.29 32.90% 3Y
-1.86 28.48% 5Y
-2.01 30.09% 10Y
-2.53 35.14% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.51 9.85%
ISIN
US01438T1060
Symbol
ALDX
Industry

Key metrics

Basic
Market capitalization
$281.0m
Enterprise Value
$220.9m
Net debt
positive
Cash
$75.3m
Shares outstanding
60.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 11.4
EV/Sales
- | 8.9
EV/FCF
negative
P/B
5.7
Financial Health
Equity Ratio
67.9%
Return on Equity
-78.7%
ROCE
-91.6%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $24.7m
EBITDA
$-44.9m | $-54.9m
EBIT
$-45.2m | $-18.2m
Net Income
$-43.2m | $-17.3m
Free Cash Flow
$-40.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
9.1% | 8.3%
EBIT
9.0% | 69.8%
Net Income
3.6% | 69.1%
Free Cash Flow
-30.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -221.9%
EBIT
-
Net
- | -69.9%
Free Cash Flow
-
More
EPS
$-0.7
FCF per Share
$-0.7
Short interest
10.6%
Employees
9
Rev per Employee
$0.0
Show more

Is Aldeyra Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Aldeyra Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Aldeyra Therapeutics, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Aldeyra Therapeutics, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Aldeyra Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.19 9.19
22% 22%
-
- Research and Development Expense 36 36
5% 5%
-
-45 -45
9% 9%
-
- Depreciation and Amortization 0.25 0.25
0% 0%
-
EBIT (Operating Income) EBIT -45 -45
9% 9%
-
Net Profit -43 -43
4% 4%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aldeyra Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aldeyra Therapeutics, Inc. Stock News

Positive
Seeking Alpha
5 days ago
Aldeyra's Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a procedural PDUFA extension. Reproxalap's Chamber Phase 3 trial met symptom endpoints with rapid, durable relief. However, the main risk is that the field trial missed the primary symptom endpoint while showing supportive signals.
Neutral
Seeking Alpha
20 days ago
Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript
Neutral
Business Wire
20 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (N...
More Aldeyra Therapeutics, Inc. News

Company Profile

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Head office United States
CEO Todd Brady
Employees 9
Founded 2004
Website www.aldeyra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today